Biotech Archives - Page 29 of 795

1 minute read

Atara Biotherapeutics Submits Tabelecleucel BLA For Treatment Of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease With U.S. FDA; Acceptance Of BLA Will Trigger $20M Milestone Payment From Pierre Fabre Laboratories, With Potential…

May 20, 9:27 AM

First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug AdministrationIf Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLDAcceptance of BLA Will Trigger $20 Million Milestone Payment

ATRA

1 minute read

GRI Bio Presents Preclinical Data Demonstrating GRI-0621 Reduces The Important Inflammatory And Fibrotic Drivers In Idiopathic Pulmonary Fibrosis

By Benzinga Newsdesk

May 20, 8:52 AM

Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of type 1 invariant Natural Killer T (iNKT) cell activity led to a decrease in fibrosis score and total lung

GRI

1 minute read

CSL and Arcturus Therapeutics Announce Nature Communications Has Published Pivotal Data Demonstrating Efficacy And Tolerability Of COVID-19 Vaccine

By Benzinga Newsdesk

May 20, 8:42 AM

Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These results add to recently published data on ARCT-154 demonstrating superior immunogenicity to Omicron

ARCT

1 minute read

Johnson & Johnson Reports TREMFYA QUASAR Maintenance Study In UC Met Its Primary Endpoint And All Major Secondary Endpoints, Including Highly Statistically Significant Rates Of Endoscopic Remission

By Benzinga Newsdesk

May 20, 8:11 AM

Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients with moderately to severely active ulcerative colitisa (UC)

JNJ

1 minute read

Ensysce Biosciences Renews Collaboration With Quotient Sciences To Undertake The Study PF614-MPAR-102 To Examine And Evaluate The Full Commercial Dose Range Of The PF614-MPAR Drug Product

By Benzinga Newsdesk

May 20, 8:07 AM

New Study to Confirm Overdose Protection Across Full Dosage Range of Breakthrough Therapy Opioid PF614-MPARSAN DIEGO, CA / ACCESSWIRE / May 20, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"),

ENSC

1 minute read

Dyne Therapeutics Announced Clinical Data From Its Ongoing Phase 1/2 ACHIEVE Trial Of DYNE-101 In Myotonic Dystrophy Type 1 And Phase 1/2 DELIVER Trial Of DYNE-251 In Duchenne Muscular Dystrophy

By Benzinga Newsdesk

May 20, 6:33 AM

In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months DYNE-101 Showed Improvement in Myotonia, Muscle Strength, and Timed

DYN

1 minute read

Medtronic Affera Mapping And Ablation System With Sphere-9 Catheter Achieves Endpoints For Safety And Efficacy

By Benzinga Newsdesk

May 17, 4:34 PM

The Sphere-9 Catheter demonstrated a positive safety profile with an excellent primary safety endpoint rate of 1.4% (1.0% for the control arm). Importantly, no safety events including pulmonary vein stenosis, esophageal

MDT

2 minute read

AbbVie Is ‘Successfully Positioned To Absorb Humira Biosimilar Erosion’: Analyst

By Vandana Singh

May 17, 1:47 PM

Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humira biosimilar erosion, drive growth with Skyrizi, Rinvoq, and emraclidine, and achieve a high single-digit CAGR from 2024 to 2029.

ABBV

2 minute read

European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech

By Vandana Singh

May 17, 12:46 PM

Moderna wins a crucial legal battle at the European Patent Office against Pfizer and BioNTech over Covid-19 vaccine patents.

BNTX

1 minute read

Medtronic Presented Late-Breaking Data Showing Performance Of Its OmniaSecure Defibrillation Lead Met Its Primary Safety And Effectiveness Endpoints, Exceeding Prespecified Performance Goals, In The Global LEADR Pivotal Trial

By Benzinga Newsdesk

May 17, 11:37 AM

Global LEADR clinical trial meets safety and effectiveness objectives; results presented at Heart Rhythm 2024 and simultaneously published in Heart RhythmDUBLIN and BOSTON, May 17, 2024 /PRNewswire/ -- Medtronic plc

MDT